News Sentiment

PRLD sentiment intelligence

Prelude Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.81 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-2.1% over one week, +7.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy

Market Reaction

Balanced read

68/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -2.1% Price reacting lower
Trend fit Trend active 7.0% over four weeks
Fair value 79.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 33
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 8
marketscreener.com 5
TradingKey 5
dars.gov.et 4
Investing.com 4
TradingView 4
Moomoo 3

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 22
Analyst action 7
Regulatory and legal 2
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 63
GlobeNewswire Direct company coverage

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Prelude Therapeutics reported its first-quarter 2026 financial results, highlighting the advancement of PRT12396 into Phase 1 studies for polycythemia vera and myelofibrosis, and plans to file an IND for PRT13722, a KAT6A degrader, by mid-2026. The company appointed Charles Morri

Tone
Positive 71/100
Event
Earnings
Published
13 May 2026 10:10
Source
GlobeNewswire
Minichart Direct company coverage

Prelude Therapeutics Reports Q1 2026 Results, Advances Precision Oncology Pipeline and Extends Cash Runway to 2028

Prelude Therapeutics announced its Q1 2026 financial results, highlighting significant progress in its precision oncology pipeline, including the initiation of a Phase 1 study for PRT12396 and an upcoming IND filing for PRT13722. The company also reported a major decrease in net

Tone
Positive 77/100
Event
Earnings
Published
12 May 2026 13:09
Source
Minichart
Quiver Quantitative Direct company coverage

Prelude Therapeutics Initiates Phase 1 Study of PRT12396 and Provides R&D Pipeline Update

Prelude Therapeutics has commenced a Phase 1 study for PRT12396, a mutant-selective JAK2V617F inhibitor for polycythemia vera and myelofibrosis, and plans to file an IND for PRT13722, a KAT6A degrader, by mid-2026. The company reported a reduced net loss of $10.4 million for Q1 2

Tone
Positive 70/100
Event
Market update
Published
12 May 2026 11:14
Source
Quiver Quantitative
Stock Titan Direct company coverage

Prelude Therapeutics (NASDAQ: PRLD) trims Q1 2026 loss and extends cash runway to 2028

Prelude Therapeutics reported a significantly narrowed net loss of $10.4 million in Q1 2026, benefiting from a substantial reduction in R&D and G&A expenses, while generating $4.58 million in revenue. The company also announced an extended cash runway into the second quarter of 2

Tone
Positive 70/100
Event
Earnings
Published
12 May 2026 11:10
Source
Stock Titan
TradingView Direct company coverage

Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) — 10-Q Summary

Prelude Therapeutics Inc. (PRLD) announced its first-quarter 2026 results, reporting revenue of $4.58 million and a net loss of $(0.13) per share, significantly improved from the prior year. This financial improvement was primarily driven by upfront option-related revenue from a

Tone
Positive 72/100
Event
Earnings
Published
12 May 2026 11:09
Source
TradingView
Moomoo Direct company coverage

Prelude Therapeutics: Current Cash Runway Into 2Q 2028 >PRLD

Prelude Therapeutics' current cash reserves are projected to fund its operations and capital expenditures into the second quarter of 2028. This extension in cash runway provides the company with over two years to advance its pipeline and strategic initiatives. The announcement in

Tone
Neutral 50/100
Event
Earnings
Published
11 May 2026 00:10
Source
Moomoo
Market source Direct company coverage

Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet

Shares of Prelude Therapeutics (PRLD) have seen a 17.1% gain recently, and analysts predict a potential upside of 33.6%, with a mean target of $6.88. While price targets alone can be misleading, strong agreement among analysts on upward earnings estimate revisions suggests a legi

Tone
Positive 70/100
Event
Earnings
Published
08 May 2026 09:55
Source
Market source
GuruFocus Direct company coverage

PRLD Initiates Coverage On Prelude Therapeutics -- Price Target Announced at $9.00

D. Boral Capital has initiated coverage on Prelude Therapeutics (PRLD) with a "Buy" rating and a price target of $9.00, significantly higher than its current trading price of $4.70. Despite a low GF Score of 29/100, indicating challenges in profitability and growth, the company h

Tone
Positive 74/100
Event
Analyst action
Published
04 May 2026 14:54
Source
GuruFocus
MSN Direct company coverage

Prelude Therapeutics (PRLD) price target increased by 19.35% to 6.29

This article reports that the price target for Prelude Therapeutics (PRLD) has been increased by 19.35%, reaching $6.29. The data implicitly suggests a positive outlook for the company's stock.

Tone
Positive 85/100
Event
Guidance
Published
04 May 2026 04:39
Source
MSN
TradingView Direct company coverage

Prelude Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Prelude Therapeutics Inc (PRLD) is projected to report a loss of 24 cents per share. This information comes from an earnings preview provided by Refinitiv. The article is a brief announcement regarding the company's expected financial performance.

Tone
Negative 30/100
Event
Earnings
Published
01 May 2026 17:39
Source
TradingView
MarketBeat Direct company coverage

Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research

Zacks Research has upgraded Prelude Therapeutics (PRLD) to a "hold" rating, contributing to a consensus "Hold" with an average price target of $7.00. The company recently reported better-than-expected EPS of ($0.20) but missed revenue estimates, posting $5.64 million against a $2

Tone
Positive 65/100
Event
Earnings
Published
01 May 2026 03:09
Source
MarketBeat